Biphenyl Compounds

• 

  Subject Areas on Research

  • 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding. 
  • 4,4'-Unsymmetrically substituted 3,3'-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors. 
  • A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method. 
  • A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. 
  • ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. 
  • Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. 
  • Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. 
  • An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1. 
  • Angioedema induced by the angiotensin II blocker losartan. 
  • Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. 
  • Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. 
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Bcl-xL is an oncogenic driver in colorectal cancer. 
  • Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Cholinergic and adrenergic activating agents as antagonists of the EEG effects of hemicholinium-3. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Comparative toxicity of polychlorinated biphenyl and polybrominated biphenyl in the rat liver: light and electron microscopic alterations after subacute dietary exposure. 
  • Copper complexes containing thiosemicarbazones derived from 6-nitropiperonal: Antimicrobial and biophysical properties. 
  • Current-use flame retardants: Maternal exposure and neurodevelopment in children of the CHAMACOS cohort. 
  • Demographic and dietary risk factors in relation to urinary metabolites of organophosphate flame retardants in toddlers. 
  • Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. 
  • Diphenyl Phosphate-Induced Toxicity During Embryonic Development. 
  • Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. 
  • Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. 
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. 
  • Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. 
  • Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. 
  • Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E2 in anti-promotive process. 
  • Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. 
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat. 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. 
  • Losartan in post-transplant erythrocytosis. 
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. 
  • Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. 
  • NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. 
  • New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. 
  • Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. 
  • Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. 
  • Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. 
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 
  • Reclassifying heart failure: time for disruptive innovation? 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Role of cholinergic mechanisms in states of wakefulness and sleep. 
  • Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. 
  • Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 
  • Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. 
  • Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. 
  • Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. 
  • Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. 
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 
  • The association of urinary phosphorous-containing flame retardant metabolites and self-reported personal care and household product use among couples seeking fertility treatment. 
  • The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. 
  • The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. 
  • The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. 
  • Thromboxane binding and signal transduction in rat glomerular mesangial cells. 
  • Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats. 
  • Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. 
  • Towards establishing indicative values for metabolites of organophosphate ester contaminants in human urine.